乌司他丁治疗重症肺炎的临床疗效分析

目的分析乌司他丁对重症肺炎的治疗效果。方法选取在2016年2月—2019年2月间因重症肺炎在本院就诊治疗的114例患者作为本研究的被选取对象,为保障本研究的顺利进行将所有被选取对象随机进行分组处理,分别为治疗组(57例)与对照组(57例)。其中对照组患者在入院后应用比阿培南等常规药物进行治疗,治疗组患者则在常规药物治疗的基础上加用乌司他丁。本研究将通过比较两组被选取对象的治疗效果和治疗前后的各项血清炎性因子水平,分析乌司他丁对重症肺炎患者的治疗效果。结果在治疗前,两组患者的CRP、PCT和TNF-α等血清炎性因子指标差异无统计学意义(P>0.05);在治疗后,治疗组患者的CRP、PCT和TNF-α等血清炎性因子指标均要低于对照组,差异有统计学意义(P<0.05),且治疗组患者的治疗有效率也要高于对照组,P<0.05,差异有统计学意义。结论乌司他丁在重症肺炎患者的治疗过程中效果显著,能够有效的降低患者的各项血清炎性因子指标。

Clinical Efficacy of Ulinastatin in the Treatment of Severe Pneumonia

Objective To analyze the therapeutic effect of ulinastatin on severe pneumonia.Methods 114 patients with severe pneumonia in the hospital from February 2016 to February 2019 were selected as the subjects of this study.In order to ensure the smooth progress of this study,all the selected subjects were randomly divided into the treatment group(57 cases)and the control group(57 cases).The patients in the control group were treated with conventional drugs such as biapenem after admission,while those in the treatment group were treated with ulinastatin on the basis of conventional drugs.This study will analyze the therapeutic effect of ulinastatin on severe pneumonia patients by comparing the therapeutic effect of two groups of selected subjects and the levels of serum inflammatory factors before and after treatment.Results After the statistical software validation of the observation data of the selected subjects in the two groups,there was no statistically significant difference in the serum inflammatory factors between the two groups before treatment such as CRP,PCT,TNF-α(P>0.05);after the treatment,the serum inflammatory factors CRP,PCT,TNF-αof the patients in the treatment group were lower than the control group,the difference was statistically significant(P<0.05),the treatment efficient rate of the treatment group was better than the control group,the difference was statistically significant(P<0.05).Conclusion Ulinastatin is effective in the treatment of severe pneumonia,and can effectively reduce the serum inflammatory factors in patients with severe pneumonia.